Search Results - "Bothos, John"

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study by Dreyling, Martin, Prof Dr, Jurczak, Wojciech, MD, Jerkeman, Mats, MD, Silva, Rodrigo Santucci, MD, Rusconi, Chiara, MD, Trneny, Marek, Prof, Offner, Fritz, MD, Caballero, Dolores, MD, Joao, Cristina, Prof, Witzens-Harig, Mathias, Prof, Hess, Georg, MD, Bence-Bruckler, Isabelle, MD, Cho, Seok-Goo, Prof, Bothos, John, PhD, Goldberg, Jenna D, MD, Enny, Christopher, BS, Traina, Shana, PhD, Balasubramanian, Sriram, PhD, Bandyopadhyay, Nibedita, PhD, Sun, Steven, PhD, Vermeulen, Jessica, MD, Rizo, Aleksandra, MD, Rule, Simon, Prof

“…Summary Background Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis. Both ibrutinib and temsirolimus have shown single-agent…”
Get full text

Human LATS1 is a mitotic exit network kinase by BOTHOS, John, TUTTLE, Robyn L, OTTEY, Michelle, LUCA, Francis C, HALAZONETIS, Thanos D

“…The kinase LATS/WARTS is a tumor suppressor protein conserved in evolution, but its function at the molecular level is not well understood. We report here that…”
Get full text

The CHFR mitotic checkpoint protein delays cell cycle progression by excluding Cyclin B1 from the nucleus by SUMMERS, Matthew K, BOTHOS, John, HALAZONETIS, Thanos D

“…CHFR, a novel checkpoint gene inactivated in human cancer, delays chromosome condensation in cells treated with microtubule poisons. To understand the…”
Get full text

Defective in Mitotic Arrest 1/Ring Finger 8 Is a Checkpoint Protein That Antagonizes the Human Mitotic Exit Network by Tuttle, Robyn L, Bothos, John, Summers, Matthew K, Luca, Francis C, Halazonetis, Thanos D

“…A molecular pathway homologous to the S. cerevisiae mitotic exit network (MEN) and S. pombe septation initiation network has recently been described in higher…”
Get full text

COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer by Herbst, Roy S, Majem, Margarita, Barlesi, Fabrice, Carcereny, Enric, Chu, Quincy, Monnet, Isabelle, Sanchez-Hernandez, Alfredo, Dakhil, Shaker, Camidge, D Ross, Winzer, Leanne, Soo-Hoo, Yee, Cooper, Zachary A, Kumar, Rakesh, Bothos, John, Aggarwal, Charu, Martinez-Marti, Alex

“…Durvalumab significantly improves overall survival for patients with unresectable stage III non-small-cell lung cancer and no progression after concurrent…”
Get full text

Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide by de Bono, Johann S, Fleming, Mark T, Wang, Judy S, Cathomas, Richard, Miralles, Manuel Selvi, Bothos, John, Hinrichs, Mary Jane, Zhang, Qu, He, Peng, Williams, Marna, Rosenbaum, Anton I, Liang, Meina, Vashisht, Kapil, Cho, Song, Martinez, Pablo, Petrylak, Daniel P

“…MEDI3726 is an antibody-drug conjugate targeting the prostate-specific membrane antigen and carrying a pyrrolobenzodiazepine warhead. This phase I study…”
Get full text

MEDI3726, a prostate-specific membrane antigen (PSMA)-targeted antibody-drug conjugate (ADC) in mCRPC after failure of abiraterone or enzalutamide by De Bono, Johann S., Fleming, Mark T., Wang, Judy Sing-Zan, Cathomas, Richard, Williams, Marna, Bothos, John G., Balic, Kemal, Cho, Song Hye, Martinez, Pablo, Petrylak, Daniel Peter

“…Abstract only 99 Background: MEDI3726 is an ADC targeting PSMA. Once bound to PSMA and internalized, the released pyrrolobenzodiazepine dimer toxin crosslinks…”
Get full text

Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies by SALGIA, Ravi, PATEL, Premal, PETERSON, Amy, RATAIN, Mark J, POLITE, Blase, MEHNERT, Janice M, MOSS, Rebecca A, BOTHOS, John, WEI YU, EPPLER, Steve, HEGDE, Priti, SHUANG BAI, KAUR, Surinder, NIJEM, Ihsan, CATENACCI, Daniel V. T

“…This first-in-human study evaluated the safety, immunogenicity, pharmacokinetics, and antitumor activity of onartuzumab, a monovalent antibody against the…”
Get full text

ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study by Maris, Michael, Salles, Gilles, Kim, Won Seog, Kim, Tae Min, Lyons, Roger M., Arellano, Martha, Karmali, Reem, Schiller, Gary, Cull, Elizabeth, Abboud, Camille N., Batlevi, Connie, Kagiampakis, Ioannis, Rebelatto, Marlon C., Lee, Young, Kirby, Lyndon C., Wang, Fujun, Bothos, John, Townsley, Danielle M., Fathi, Amir T., Ribrag, Vincent

“…Background MEDI7247 is a first-in-class antibody-drug conjugate (ADC) consisting of an anti-sodium-dependent alanine-serine-cysteine transporter 2…”
Get full text

Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors by Xin, Yan, Jin, Denise, Eppler, Stephen, Damico-Beyer, Lisa A., Joshi, Amita, Davis, John D., Kaur, Surinder, Nijem, Ihsan, Bothos, John, Peterson, Amy, Patel, Premal, Bai, Shuang

“…Onartuzumab is a unique, humanized, monovalent (one‐armed) monoclonal antibody (mAb) against the MET receptor. The intravenous (IV) pharmacokinetics (PK) of…”
Get full text

A phase 1/1b multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, immunogenicity, and antitumor activity of MEDI3726 in patients with metastatic, castration-resistant prostate cancer who have received prior treatment with abiraterone or enzalutamide by Fleming, Mark T., Cathomas, Richard, Petrylak, Daniel Peter, Wang, Judy Sing-Zan, Bander, Neil Harrison, Zammarchi, Francesca, van Berkel, Patrick H., Cho, Song Hye, Elgeioushi, Nairouz, Bothos, John, Scheuber, Anita, de Bono, Johann

“…Abstract only TPS5088 Background: Therapeutic advances have recently been achieved for patients with metastatic, castration-resistant prostate cancer (mCRPC)…”
Get full text

A phase 1 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of MEDI7247 in patients with select relapsed/refractory hematologic malignancies by Fathi, Amir Tahmasb, Donnellan, William Bruce, Lyons, Roger M., Maris, Michael B., Kim, Tae Min, Kim, Won Seog, Schiller, Gary J., Abboud, Camille N., Arellano, Martha Lucia, Cull, Elizabeth H., Yee, Karen W. L., Townsley, Danielle Michelle, Wang, Fujun, Bothos, John G., Yao, Nai-Shun, Salles, Gilles A.

“…Abstract only…”
Get full text

Lymphoma Symptoms: Data from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL) Treated with Ibrutinib Vs. Temsirolimus by Hess, Georg, Rule, Simon, Jurczak, Wojciech, Jerkeman, Mats, Santucci, Rodrigo, Rusconi, Chiara, Caballero, Dolores, Joao, Cristina M., Witzens-Harig, Mathias, Bence-Bruckler, Isabelle, Cho, Seok-Goo, Bandyopadhyay, Nibedita, Goldberg, Jenna, Bothos, John, Enny, Christopher, Vermeulen, Jessica, Traina, Shana, Dreyling, Martin H.

“…Introduction MCL is an incurable aggressive B-cell lymphoma with a poor overall prognosis. For patients with MCL who fail initial therapy (ie, with relapsed or…”
Get full text

Ibrutinib Vs Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL) by Rule, Simon, Jurczak, Wojciech, Jerkeman, Mats, Santucci, Rodrigo, Rusconi, Chiara, Trneny, Marek, Offner, Fritz, Caballero, Dolores, Joao, Cristina, Witzens-Harig, Mathias, Hess, Georg, Bence-Bruckler, Isabelle, Cho, Seok-Goo, Balasubramanian, Sriram, Bandyopadhyay, Nibedita, Sun, Steven, Goldberg, Jenna, Bothos, John, Traina, Shana, Enny, Christopher, Rizo, Aleksandra, Vermeulen, Jessica, Dreyling, Martin H.

“…Introduction MCL is an aggressive B-cell lymphoma with a poor overall prognosis. For patients who fail initial therapy, conventional chemotherapy achieves only…”
Get full text

The Chfr mitotic checkpoint protein functions with Ubc13-Mms2 to form Lys63-linked polyubiquitin chains by Bothos, John, Summers, Matthew K, Venere, Monica, Scolnick, Daniel M, Halazonetis, Thanos D

“…We recently described a novel checkpoint pathway that functions early in mitosis to delay chromosome condensation in response to microtubule poisons. The only…”
Get full text

Abstract 4717: Final results from the Phase I study of MetMAb, a monovalent antagonist antibody to the receptor Met, dosed as single agent and in combination with bevacizumab in patients with advanced solid malignancies by Moss, Rebecca A., Bothos, John G., Patel, Premal H., Peterson, Amy C., Eppler, Steve, Bai, Shuang, Nijem, Ihsan, Desnoyers, Luc, Kaur, Surinder, Zha, Jiping, Yu, Wei, Simpson, Joe, Ratain, Mark J., Tan, Antoinette R., Stein, Mark N., Mehnert, Janice M., Salgia, Ravi

“…Abstract Background: The receptor tyrosine kinase Met and/or its ligand, hepatocyte growth factor (HGF), are frequently over-expressed in cancers. Aberrant Met…”
Get full text

Abstract 2774: Complete results from a phase Ia dose-escalation and dose-expansion study of single-agent MetMAb, a monovalent antagonist antibody to the receptor MET, administered intravenously in patients with locally advanced or metastatic solid tumors by Salgia, Ravi, Peterson, Amy C., Bothos, John, Eppler, Steve, Yu, Wei, Hegde, Priti, Yauch, Bob, Zha, Jiping, Ratain, Mark J., Geary, David, Wesolowsky, Elayne, LaRosiliere, Marjorie, Patel, Premal, Moss, Rebecca

“…Abstract COMPLETE RESULTS FROM A PHASE Ia DOSE-ESCALATION AND DOSE-EXPANSION STUDY OF SINGLE-AGENT MetMAb, A MONOVALENT ANTAGONIST ANTIBODY TO THE RECEPTOR…”
Get full text

Crystal Structure of a Human Mob1 Protein: Toward Understanding Mob-Regulated Cell Cycle Pathways by Stavridi, Elena S, Harris, Kimberly G, Huyen, Yentram, Bothos, John, Verwoerd, Peter-Mark, Stayrook, Steve E, Pavletich, Nikola P, Jeffrey, Philip D, Luca, Francis C

“…The Mob protein family comprises a group of highly conserved eukaryotic proteins whose founding member functions in the mitotic exit network. At the molecular…”
Get full text

Inactivating mutations targeting the chfr mitotic checkpoint gene in human lung cancer by MARIATOS, George, BOTHOS, John, ZACHARATOS, Panayotis, SUMMERS, Matthew K, SCOLNICK, Daniel M, KITTAS, Christos, HALAZONETIS, Thanos D, GORGOULIS, Vassilis G

“…A hallmark of cancer is inactivation of cell cycle checkpoints. However, very few mutations targeting mitotic checkpoint genes have been described, and in…”
Get full text

The Chfr mitotic checkpoint protein functions with Ubcl3-Mms2 to form Lys63-linked polyubiquitin chains by BOTHOS, John, SUMMERS, Matthew K, VENERE, Monica, SCOLNICK, Daniel M, HALAZONETIS, Thanos D

Get full text